After stratification according to tumor size, patients with TP53 missense mutation instead of truncating mutation showed significant higher metastatic rate than those without TP53 mutation (metastatic rate: 20.5% in KRASmutTP53missense PDAC vs. 2.9% in KRASmutTP53WT PDAC, P = 0.030), indicating that TP53 missense mutation probably led to early invasiveness and metastasis in KRASmut PDAC patients. This evidence concerns the gene TP53 and neoplasm.